Cargando…
A case report of disseminated verrucosis secondary to ustekinumab in a patient with Crohn’s disease
Ustekinumab is a biologic agent with Food and Drug Administration approval for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. It functions to inhibit the p40 subunit common to both interleukin-12 and interleukin-23. These pro-infla...
Autores principales: | Svoboda, Steven A, Rush, Patrick S, Sharghi, Kevin G, Rady, Peter L, Tyring, Stephen K, Eikenberg, Joshua D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975484/ https://www.ncbi.nlm.nih.gov/pubmed/33796316 http://dx.doi.org/10.1177/2050313X211003056 |
Ejemplares similares
-
Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report
por: Vallerand, Isabelle A, et al.
Publicado: (2019) -
Epidermolysis bullosa acquisita treated with ustekinumab: A case
report
por: Prosty, Connor, et al.
Publicado: (2022) -
Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023) -
A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report
por: DeBiasio, Celina, et al.
Publicado: (2022) -
Primary Cutaneous Nocardiosis in an Adolescent with Crohn Disease
por: Svoboda, Steven A., et al.
Publicado: (2020)